Ferumoxytol-enhanced MR angiography was technically feasible and provided excellent image quality in 99% of evaluated vascular segments for pre-TAVR mapping in patients with renal impairment.
Cross-Sectional (n=26)
Single-blind
No
Does ferumoxytol-enhanced MR angiography provide feasible and reliable vascular access mapping before TAVR in patients with renal impairment?
Ferumoxytol-enhanced MR angiography provides reliable vascular mapping for TAVR planning in patients with renal impairment, avoiding nephrotoxic contrast agents.
Purpose To assess the technical feasibility of the use of ferumoxytol-enhanced (FE) magnetic resonance (MR) angiography for vascular mapping before transcatheter aortic valve replacement in patients with renal impairment. Materials and Methods This was an institutional review board–approved and HIPAA-compliant study. FE MR angiography was performed at 3.0 T or 1.5 T. Unenhanced computed tomographic (CT) images were used to overlay vascular calcification on FE MR angiographic images as composite fused three-dimensional data. Image quality of the subclavian and aortoiliofemoral arterial tree and confidence in the assessment of calcification were evaluated by using a four-point scale (4 = excellent vascular definition or strong confidence). Signal intensity nonuniformity as reflected by the heterogeneity index (ratio between the mean standard deviation of luminal signal intensity and the mean luminal signal intensity), signal-to-noise ratio, and consistency of luminal diameter measurements were quantified. Findings at FE MR angiography were compared with pelvic angiograms. Results Twenty-six patients underwent FE MR angiography without adverse events. A total of 286 named vascular segments were scored. The image quality score was 4 for 99% (283 of 286) of the segments (κ = 0.9). There was moderate to strong confidence in the ability to assess vascular calcific morphology in all studies with complementary unenhanced CT. The steady-state luminal heterogeneity index was low, and signal-to-noise ratio was high. Interobserver luminal measurements were reliable (intraclass correlation coefficient, 0.98; 95% confidence interval: 0.98, 0.99). FE MR angiographic findings were consistent with correlative pelvic angiograms in all 16 patients for whom the latter were available. Conclusion In patients with renal impairment undergoing transcatheter aortic valve replacement, FE MR angiography is technically feasible and offers reliable vascular mapping without exposure to iodine- or gadolinium-based contrast agents. Thus, the total cumulative dose of iodine-based contrast material is minimized and the risk of acute nephropathy is reduced. © RSNA, 2017 Online supplemental material is available for this article.
Nguyen et al. (Tue,) conducted a cross-sectional in Chronic kidney disease requiring TAVR vascular mapping (n=26). Ferumoxytol-enhanced MR angiography (FE-MRA) was evaluated on Image quality score of 4 (excellent vascular definition) for named vascular segments. Ferumoxytol-enhanced MR angiography was technically feasible and provided excellent image quality in 99% of evaluated vascular segments for pre-TAVR mapping in patients with renal impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: